Changes in plasma histamine concentration in the streptozotocin-diabetic rat

Theodore M. Hollis, John A. Kern, Ned A. Enea, Andrew J. Cosgarea

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Plasma histamine concentrations were measured in rats made diabetic via jugular vein injection of streptozotocin and held 4 weeks following diabetes diagnosis. At least 15 diabetic animals received insulin (6-8 U/day) or α-hydrazinohistidine (α-HH) for the last week of the holding period. α-HH is a specific inhibitor of histidine decarboxylase (HD), the principle histamine-forming enzyme in mammals. Plasma histamine concentrations, expressed as means and mean standard errors (ng/ml) were as follows: control, 25.5 ± 2.4; diabetic, 47.1 ± 5.2; diabetic-insulin, 34.6 ± 2.9; diabetic-α-HH, 28.1 ± 2.1. These data indicate that in experimental diabetes there is an expansion of the nascent, or inducible histamine pool, an increase which is reflected by increased circulating plasma histamine. This may be one component mediating altered microvessel as well as large vessel permeability characteristics, an underlying component of both diabetic microangiopathy and macroangiopathy.

Original languageEnglish (US)
Pages (from-to)90-96
Number of pages7
JournalExperimental and Molecular Pathology
Issue number1
StatePublished - Aug 1985
Externally publishedYes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Clinical Biochemistry


Dive into the research topics of 'Changes in plasma histamine concentration in the streptozotocin-diabetic rat'. Together they form a unique fingerprint.

Cite this